EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Runfeng Zhang iD, Hong Yu iD, Miao Chen iD, Xiaoqi Qin, Jie Xiao iD, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang iD, Wei Wang und 4 weitere

British Journal of Haematology · 2026-11 · 209 (5) · 2316-2320

DOI: 10.1111/bjh.70806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 30.08.2026. Verfasst von Runfeng Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chinese Academy of Medical College & Peking Union Medical College Hospital, Beijing, China. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

immunomodulating drugsixazomibmultiple myelomaphase IV clinical trialpomalidomideproteasome inhibitorsrecurrence

Autor:innen und Institutionen

  • Department of Internal Medicine, Chinese Academy of Medical College & Peking Union Medical College Hospital, Beijing, China.
  • Department of Hematology, Chinese Academy of Medical College & Peking Union Medical College Hospital, Beijing, China.
  • Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
  • Hematology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.

ORCID-Profile: Runfeng Zhang, Hong Yu, Miao Chen, Jie Xiao, Jingcheng Zhang, Yanping Ma, Rong Fu, Junling Zhuang

Förderung

  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Zhang, R., Yu, H., Chen, M., Qin, X., Xiao, J., Leng, Y., Zhao, M., Yu, J., Qin, C., Wang, X., Zhang, J., Wang, W., Chen, W., Ma, Y., Fu, R., & Zhuang, J. (2026). A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 209(5), 2316-2320. https://doi.org/10.1111/bjh.70806

Vancouver

Zhang R, Yu H, Chen M, Qin X, Xiao J, Leng Y, et al. A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 2026;209(5):2316-2320. doi:10.1111/bjh.70806

BibTeX
@article{Zhang2026,
  author = {Zhang, Runfeng and Yu, Hong and Chen, Miao and Qin, Xiaoqi and Xiao, Jie and Leng, Yun and Zhao, Mingzhe and Yu, Jie and Qin, Chunjie and Wang, Xiuju and Zhang, Jingcheng and Wang, Wei and Chen, Wenming and Ma, Yanping and Fu, Rong and Zhuang, Junling},
  title = {A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {5},
  pages = {2316--2320},
  doi = {10.1111/bjh.70806}
}
Kostenlos starten →